OneSpan Inc vs 10X Genomics Inc — how do they compare? OneSpan Inc trades at $17.96 (market cap $662.97M), while 10X Genomics Inc trades at $79.21 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 15.2× OneSpan Inc's market cap, and OneSpan Inc pays a 2.89% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold OneSpan Inc for 18 Days and 10X Genomics Inc for 92 Days on average.
| OSPN | TXG | |
|---|---|---|
Market Cap | $662.97M | $10.07B |
Volume | 616,882 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $18.42 | $97.74 |
52-Week Low | $10.15 | $11.48 |
Typical Hold Time | 18 Days | 92 Days |
Enterprise Value | $632.05M | $9.59B |
Dividend Yield | 2.89% | — |
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $17.70, down 3.7% in the last session, but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows a bullish technical signal with support at $17 and resistance at $18. Recent Q2 2026 results exceeded expectations with EPS of $0.30 versus $0.231 expected, while the company introduced new authentication technology to drive future growth.
The outlook remains positive given strong analyst support (66.7% buy ratings) and solid financial metrics, though investors should monitor declining cash flow trends and competitive pressures in the cybersecurity sector. The stock presents value opportunity with P/E of 10.16 and ROE of 26.51%, but faces execution risks in maintaining subscription revenue growth.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →